Research programme: somatostatin analogues - Ardana

Drug Profile

Research programme: somatostatin analogues - Ardana

Alternative Names: Somatostatin analogues research programme - Ardana

Latest Information Update: 25 Oct 2006

Price : $50

At a glance

  • Originator Ardana Bioscience
  • Class
  • Mechanism of Action Somatotropin receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 25 Aug 2002 Europeptides has been acquired from Zentaris AG by Ardana Bioscience
  • 19 May 2000 Preclinical development for Cancer in France (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top